MARK2 and head and neck cancer: Serine/threonine protein kinase AKT, an important target of the phosphoinositide‐3‐kinase/AKT signaling pathway, is abnormally activated in various types of tumor, including those in head and neck cancer (Amornphimoltham et al., 2004) (including OTSCC) (Massarelli et al., 2005).